Since five decades, complement-dependent cytotoxicity crossmatch (CDCXM) has been considered an important tool to assess the immunological risk, wherein the recipient's plasma is incubated with donor lymphocytes in the presence of complement factors.
This is a case report of successful kidney transplantation in a patient who had positive complement-dependent crossmatch because of autoantibodies and negative flow cytometry crossmatch (FCXM) and she was devoid of donor-specific antibodies.
CasE rEport
A 23-year-old female patient developed peripheral antineutrophil cytoplasmic antibody-associated vasculitis with end-stage renal disease. She was on maintenance hemodialysis through left brachiocephalic fistula twice per week for 1 year. She was admitted for RT with cross donor in view of ABO incompatibility with mother.
Lymphocyte crossmatching was performed using AHG-CDCXM 80% (positive). Auto crossmatching was done which was 50% (positive). Dithioerythritol (DTT) was used to treat recipient's serum to exclude IgM antibodies; DTT-CDCXM was 10% (negative). Hence, it was concluded that CDCXM positivity was secondary to IgM antibodies. To confirm the same, FCXM was performed using FACSCanto™ cytometer.
T-and B-lymphocytes were phycoerythrin stained and were conjugated with mouse monoclonal antibodies specific for human CD3 and CD19, respectively. FCXM was negative.
LUMINEXX platform (LAB screen, One Lambda, Inc. Canoga Park, CA) was used to measure donor-specific antibodies. DSA was found to be negative.
The patient was induced with rabbit antithymocyte globulin (1.5 mg/kg) and she had also received three doses of methylprednisolone 500 mg each.
Maintenance immunosuppression comprised prednisolone 20 mg OD, tacrolimus (0.05 mg/kg) in two divided doses, and mycophenolic acid sodium salt 360 mg QID.
On the day of transplant, the patient achieved urine output of approximately 11 L. The patient's serum creatinine level on postoperative day (POD) 2 was 0.7 mg/dl. Central venous access and drains were removed on POD 3 and per urethral catheter was removed on POD 5. The patient's graft Doppler study was performed on immediate PO period and then on POD 3 which was normal with average resistive index (RI) of 0.6.
Trough tacrolimus level was performed on POD 4 using the immunoassay method which was 9.72 ng/ml. The patient was discharged in stable condition on POD 7.
disCussion
A CDCXM detects both IgG and/or IgM complement fixing antibodies. [4] AHG-CDCXM is more sensitive and can detect antibodies in low titers, but it is less sensitive than FCXM and DSA. [5] Treating recipient serum with DTT, that is, DTT excludes IgM antibodies, which are considered to be innocent in transplant immunology.
FCXM uses IgG-FITC label and hence it cannot detect IgM antibodies. [6] FCXM can therefore detect both complements fixing as well as complement nonfixing IgG antibodies even when they are present in low titers. Therefore, a positive CDCXM with negative FCXM suggests the presence of IgM antibodies and absence of IgG antibodies, that is, AHG-CDCXM positive, DTT-CDCXM negative, and FCXM negative.
Luminex DSA using single antigen beads is considered most sensitive and can detect both IgG and IgM donor-specific antibodies either complement fixing or complement nonfixing. [7] In our case, it were the autoantibodies which were responsible for the CDCXM false positivity which could be identified only with more sensitive means of crossmatch examination such as FCXM and DSA.
ConClusion
All the three modalities, that is, CDCXM, FCXM, and DSA are important to assess an individual's immunological risk and interpreting all test results in a comprehensive manner can help identify false-positive and false-negative test results.
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